Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study
- PMID: 29124399
- DOI: 10.1007/s00296-017-3878-z
Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study
Abstract
To investigate the association of age and other factors with thrombosis risk in antiphospholipid antibody (aPL) carriers, a retrospective observational study was conducted in a cohort of patients with medium-high aPL titres recruited in a tertiary care hospital. Assuming an age difference of 9.8 years between patients with and without thrombosis, we estimated that a sample size of 70 participants was required. Several variables besides age including gender, vascular risk factors, inherited thrombophilias, non-thrombotic clinical manifestations, laboratory parameters, aPL profile, length of aPL exposure, antithrombotic drugs and partial aPL score were assessed by univariate analysis followed by multivariate logistic regression. Outcomes were analysed by whether thromboses occurred before (model 1) or after (model 2) aPL detection. Seventy patients [50 females; median (interquartile range) baseline age: 46.99 (39.39-66.20) years] were followed for 2.59 (0.67-5.86) years. Overall, 18 and 5 thromboses were diagnosed applying models 1 and 2, respectively. Time to thrombosis after aPL detection was 2.10 (1.03-8.24) years. Age did not differ between patients with and without thrombosis using models 1 (p = 0.92) or 2 (p = 0.67). Instead, we identified other predictors of thrombosis, namely, lack of thromboprophylaxis [odds ratio (OR) 13.50, 95% confidence interval (95% CI) 1.02-178.05, p = 0.048] and length of aPL exposure (OR 1.41, 95% CI 1.04-1.92, p = 0.026) in model 2, while lupus anticoagulant showed a tendency to increase the risk (OR 7.10, 95% CI 0.86-58.78, p = 0.069) in model 1. Unlike age, lack of thromboprophylaxis, prolonged aPL exposure and lupus anticoagulant may increase the risk of thrombosis in aPL carriers.
Keywords: Age factors; Antibodies; Antiphospholipid; Risk factors; Thrombosis.
Similar articles
-
Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity.Lupus. 2017 Feb;26(2):163-169. doi: 10.1177/0961203316657433. Epub 2016 Jul 20. Lupus. 2017. PMID: 27432808
-
Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.Lupus. 2014 Dec;23(14):1468-76. doi: 10.1177/0961203314545410. Epub 2014 Aug 27. Lupus. 2014. PMID: 25164304
-
Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients.Lupus. 2007;16(1):39-45. doi: 10.1177/0961203306074767. Lupus. 2007. PMID: 17283584
-
Antiphospholipid antibodies: evaluation of the thrombotic risk.Thromb Res. 2012 Oct;130 Suppl 1:S37-40. doi: 10.1016/j.thromres.2012.08.270. Thromb Res. 2012. PMID: 23026657 Review.
-
Clinical profiles and risk assessment in patients with antiphospholipid antibodies.Expert Rev Clin Immunol. 2019 Jan;15(1):73-81. doi: 10.1080/1744666X.2019.1543025. Epub 2018 Nov 13. Expert Rev Clin Immunol. 2019. PMID: 30381978 Review.
Cited by
-
Evaluation of Frequency, Clinical Correlation, and Antibodies Confirmation Profile in Patients with Suspected Antiphospholipid Syndrome.TH Open. 2021 Oct 19;5(4):e470-e478. doi: 10.1055/s-0041-1736289. eCollection 2021 Oct. TH Open. 2021. PMID: 34693196 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical